Study of Busulfan for Refractory Central Nervous System (CNS) Tumors
Status:
Withdrawn
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This protocol is aimed at establishing a maximum tolerated dose (MTD) for submyeloablative
doses of Busulfex ® with the hope that a tolerable, submyeloablative dose can be established
to test efficacy as alternative therapy for refractory pediatric brain tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago